Are there protective treatments for cognitive decline in MS?

Journal of the Neurological Sciences

Volumn 245, Issue 1-2, 2006, Pages 183-186

  Amato, Maria Pia ^a   Portaccio, Emilio ^a   Zipoli, Valentina ^a  

^a UNIVERSITY OF FLORENCE   (Italy)

Author keywords

Cognitve dysfunction; Multiple sclerosis; Treatment strategies

Indexed keywords

3 AMINOPYRIDINE; 4 AMINOPYRIDINE; AMANTADINE; BETA INTERFERON; BETA1A INTERFERON; GALANTAMINE; GLATIRAMER; INTERFERON BETA SERINE; PEMOLINE; PLACEBO;

ALZHEIMER DISEASE; ARTICLE; COGNITIVE DEFECT; COGNITIVE REHABILITATION; FATIGUE; HUMAN; MULTIPLE SCLEROSIS; PRIORITY JOURNAL;

CHOLINESTERASE INHIBITORS; COGNITION DISORDERS; COGNITIVE THERAPY; HUMANS; INTERFERON-BETA; MULTIPLE SCLEROSIS;

EID: 33646832088     PISSN: 0022510X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jns.2005.07.017     Document Type: Article

References (22)

1. Bobholz J.A., and Rao S.M. Cognitive dysfunction in multiple sclerosis: a review of recent developments. Curr Opin Neurol 16 3 (2003) 283-288
2. Amato M.P., Ponziani G., Siracusa G., and Sorbi S. Cognitive dysfunction in early-onset multiple sclerosis: a reappraisal after 10 years. Arch Neurol 58 10 (2001) 1602-1606
3. Amato M.P., Ponziani G., Pracucci G., Bracco L., Siracusa G., and Amaducci L. Cognitive impairment in early-onset multiple sclerosis. Pattern, predictors, and impact on everyday life in a 4-year follow-up. Arch Neurol 52 2 (1995) 168-172
4. Rao S.M., Leo G.J., Ellington L., Nauertz T., Bernardin L., and Unverzagt F. Cognitive dysfunction in multiple sclerosis. II. Impact on employment and social functioning. Neurology 41 5 (1991) 692-696
5. Amato M.P., and Zipoli V. Clinical management of cognitive impairment in multiple sclerosis: a review of current evidence. Int MS J 10 3 (2003) 72-83
6. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. The IFNB Multiple Sclerosis Study Group. Neurology 43 4 (1993) 655-661
7. Pliskin N.H., Hamer D.P., Goldstein D.S., Towle V.L., Reder A.T., Noronha A., et al. Improved delayed visual reproduction test performance in multiple sclerosis patients receiving interferon beta-1b. Neurology 47 6 (1996) 1463-1468
8. Barak Y., and Achiron A. Effect of interferon-beta-1b on cognitive functions in multiple sclerosis. Eur Neurol 47 1 (2002) 11-14
9. Johnson K.P., Brooks B.R., Cohen J.A., Ford C.C., Goldstein J., Lisak R.P., et al. Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group. Neurology 45 7 (1995) 1268-1276
10. Weinstein A., Schwid S.R., Schiffer R.B., McDermott M.P., Giang D.W., and Goodman A.D. Neuropsychologic status in multiple sclerosis after treatment with glatiramer. Arch Neurol 56 3 (1999) 319-324
11. Fischer J.S., Priore R.L., Jacobs L.D., Cookfair D.L., Rudick R.A., Herndon R.M., et al. Neuropsychological effects of interferon beta-1a in relapsing multiple sclerosis. Multiple Sclerosis Collaborative Research Group. Ann Neurol 48 6 (2000) 885-892
12. Jacobs L.D., Cookfair D.L., Rudick R.A., Herndon R.M., Richert J.R., Salazar A.M., et al. Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG). Ann Neurol 39 3 (1996) 285-294
13. Bakshi R. Fatigue associated with multiple sclerosis: diagnosis, impact and management. Mult Scler 9 3 (2003) 219-227
14. Cohen R.A., and Fisher M. Amantadine treatment of fatigue associated with multiple sclerosis. Arch Neurol 46 6 (1989) 676-680
15. Geisler M.W., Sliwinski M., Coyle P.K., Masur D.M., Doscher C., and Krupp L.B. The effects of amantadine and pemoline on cognitive functioning in multiple sclerosis. Arch Neurol 53 2 (1996) 185-188
16. Smits R.C., Emmen H.H., Bertelsmann F.W., Kulig B.M., van Loenen A.C., and Polman C.H. The effects of 4-aminopyridine on cognitive function in patients with multiple sclerosis: a pilot study. Neurology 44 9 (1994) 1701-1705
17. Rossini P.M., Pasqualetti P., Pozzilli C., Grasso M.G., Millefiorini E., Graceffa A., et al. Fatigue in progressive multiple sclerosis: results of a randomized, double-blind, placebo-controlled, crossover trial of oral 4-aminopyridine. Mult Scler 7 6 (2001) 354-358
18. Bever Jr. C.T., Anderson P.A., Leslie J., Panitch H.S., Dhib-Jalbut S., Khan O.A., et al. Treatment with oral 3,4 diaminopyridine improves leg strength in multiple sclerosis patients: results of a randomized, double-blind, placebo-controlled, crossover trial. Neurology 47 6 (1996) 1457-1462
19. Rammohan K.W., Rosenberg J.H., Lynn D.J., Blumenfeld A.M., Pollak C.P., and Nagaraja H.N. Efficacy and safety of modafinil (Provigil) for the treatment of fatigue in multiple sclerosis: a two centre phase 2 study. J Neurol Neurosurg Psychiatry 72 2 (2002) 179-183
20. Amato M.P. Donepezil for memory impairment in multiple sclerosis. Lancet Neurol 4 2 (2005) 72-73
21. Krupp L.B., Christodoulou C., Melville P., Scherl W.F., MacAllister W.S., and Elkins L.E. Donepezil improved memory in multiple sclerosis in a randomized clinical trial. Neurology 63 9 (2004) 1579-1585
22. Lincoln N.B., Dent A., Harding J., Weyman N., Nicholl C., Blumhardt L.D., et al. Evaluation of cognitive assessment and cognitive intervention for people with multiple sclerosis. J Neurol Neurosurg Psychiatry 72 1 (2002) 93-98